AKT inhibitor VIII NEW
| Price | $44 | $61 | $107 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: AKT inhibitor VIII | CAS No.: 612847-09-3 |
| Purity: 98.77% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | AKT inhibitor VIII |
| Description | AKT inhibitor VIII (AKTi-1/2) is a highly specific inhibitor of Akt1/2, with IC50 values of 58 nM and 210 nM respectively, demonstrating approximately 36-fold greater selectivity for Akt1 over Akt3. |
| Cell Research | The cell growth inhibitory effect of AKTi-1/2 is studied using the 96 h sulforhodamine B assay (SRB). Drug concentrations that inhibited 50% of cell growth (IC50) are calculated for each compound in GraphPad Prism 6.0 using non-linear regression analysis and sigmoidal dose–response (variable slope) equation.(Only for Reference) |
| Kinase Assay | Kinase screen: Briefly, all assays (25.5 μl at 21°C for 30 min) are performed using a Biomek 2000 Laboratory Automation Workstation in a 96-well format. Reactions contains 5–20 mU purified kinase along with substrate peptide or protein and are initiated by the addition of 10 mM MgAcetate and 5, 20, or 50 μM ATP ([γ-33P]-ATP, 800 cpm/pmol). |
| In vitro | Akti-1/2 (50 mg/kg, i.p.) inhibits both basal and IGF-stimulated Akt1/2 phosphorylation in the lungs of mice. |
| In vivo | In cell-based IPKA (C33A) assays, AKT inhibitor VIII suppresses Akt1/2 with IC50 values of 305 and 2086 nM, respectively. It significantly increases caspase-3 activity, inducing apoptosis in MCF7, HT29, and A2780 cells. In hepatocytes, it inhibits insulin's regulation of PEPCK and the expression of G6Pase and FOXO1 activity. Additionally, AKT inhibitor VIII enhances PAR-1-mediated platelet aggregation by blocking PKB. It inhibits cell growth in HCC827, NCI-H522, NCI-1651, and PC-9 cells with IC50 values of 4.7, 7.25, and 9.5 μM, respectively. When combined with gefitinib, the effects of suppressing cell growth and inducing apoptosis are enhanced. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 11 mg/mL (20 mM), Heating is recommended. |
| Keywords | PKB | Inhibitor | AKT inhibitor VIII | Akt | Apoptosis | Protein kinase B | inhibit |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | 2,3-Butanediol |
| Related Compound Libraries | Highly Selective Inhibitor Library | Apoptosis Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $138.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/5Kg |
VIP1Y
|
SHANGHAI GEM CHEMICAL INDUSTRY CO.,LTD.
|
2024-12-23 | |
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY